Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NRX Pharmaceuticals Inc NRXP

Financial Services Healthcare
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.


NDAQ:NRXP - Post by User

NRX Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by AviseAnalyticson Oct 19, 2021 8:05am
184 Views
Post# 34021288

ALL YOU NEED TO KNOW ABOUT NRX PHARMACEUTICALS!

ALL YOU NEED TO KNOW ABOUT NRX PHARMACEUTICALS!$NRXP

There is a lot of buzz around NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing ZYESAMI™ (AVIPTADIL®) for the treatment of respiratory failure in critical COVID-19 patients.

The Company has recently submitted a revised Investigational New Drug (IND) module for ZYESAMI, which was met with much cheer by the investors. 
However, RELIEF THERAPEUTICS Holding AG has filed a lawsuit against the Company, claiming failure to honor its obligations under the collaboration agreement entered between the companies in September 2020. 

Read on to find out more!

https://www.aviseanalytics.com/all-you-need-to-know-about-nrx-pharmaceuticals/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities